Management
Richard S. Kornbluth, M.D., Ph.D.
Co-Founder, President, and Chief Scientific Officer
Richard Kornbluth invented the company’s technology while serving as an Associate Professor of Medicine at the University of California San Diego (UCSD). He is both a basic scientist and a Board Certified medical internist and pulmonary specialist. His interest in immunostimulatory molecules began during a postdoctoral fellowship in tumor immunology at the Scripps Research Institute where he filed his first patent on what is now known as CD40L. At UCSD, he published more than 50 papers on the immunology and molecular virology of HIV, and wrote or co-wrote 26 funded grant applications. Richard received a Bachelor’s degree from Harvard College, M.D. from New York Medical College, and Ph.D. in Pathology from Columbia University.
David A. Roth, Ph.D.
Co-Founder and Chief Operating Officer
David Roth has extensive biotechnology management experience, including product and business development and research operations experience. He was most recently Senior Director - Research Operations at Halozyme Therapeutics, Inc. where he directed multiple preclinical R&D programs as well as several product development teams that have become registered products in partnerships with Roche and Baxter. Prior to that he was Senior Vice President for R&D at CODA Genomics (now Verdezyne, Inc.) where his duties included biologics product and technology development, strategic business planning, and alliance/partnership/collaboration development. He is the author of 36 papers and 26 patents. David received his B.S., M.S., and Ph.D. degrees from the University of California at Berkeley, with postdoctoral training at UCSD School of Medicine in La Jolla.
Marc Hertz, Ph.D.
Co-Founder and Board Chair
Marc Herz was previously CEO of Pharmexa, Inc. (formerly Epimmune, Inc.), a wholly owned subsidiary of Pharmexa A/S (CSE: PHARMX) that developed vaccines and cancer immunotherapies. At Pharmexa, he was responsible for 28 scientists and administrators and directed company strategy, business development, and investor relations. Dr. Hertz participated in multiple rounds of public fundraising that generated approximately $90 million in investments for the company. Marc received a Bachelor’s degree from Bowdoin College and his Ph.D. in Immunology from the University of Colorado Health Sciences Center and the National Jewish Medical and Research Center.
Mariusz Stempniak, Ph.D.
Principal Scientist
Mariusz Stempniak recently joined Multimeric after spending 15 years at Pfizer Global Research & Development, La Jolla, CA. While a Principal Scientist at Pfizer, he created the cell-based assay for ALK/c-Met kinase inhibitors that lead to the identification of crizotinib (Xalkori™), Pfizer’s most important new drug introduction in the last year. Mariusz received his undergraduate and Ph.D. degrees from the University of Adam Mickiewicz in Poznan, Poland.
